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Abstract 
One strategy to encourage uninsured and underinsured patients’ compliance with medication regimen is to refer them to 
pharmaceutical industry–sponsored patient assistance programs (PAPs).  In order to receive the requested medications, patients 
should be qualified based on the program eligibility requirements. The purpose of this study was to examine PAP eligibility criteria for 
the most commonly dispensed prescriptions in the United States. We identified 136 unique chemical entities in the Top 200 drug list 
and 111 (82%) of these pharmaceutical products were offered by PAPs. Among the available medications, 69 (62%) were brand 
name; 29 (26%) were generic, and 13 (12%) had both brand name/generic forms. In terms of the availability of types of drugs (brand 
name vs. generic) provided by PAPs, differences in PAP eligibility requirements were found for citizenship (p < 0.001), permanent 
residency (p < 0.001), and prescription drug coverage (p< 0.001), but not for income limits (p= 0.051). Overall, PAPs could help low-
income patients to obtain necessary medications; however, U.S. citizenship/permanent residency and restriction on prescription 
coverage are more likely to be required for brand name drugs rather than for generics. PAPs also provide some options for the 
underinsured and those with private insurance or Medicare Part D plan that offers inadequate prescription coverage. 
 
 
Introduction and Study Objective 
The rising cost of prescription drugs has been a major public 
health concern in the United States.  Current trend shows 
that pharmaceutical expenses consume a major part of total 
health care expenditure and have a significant effect on the 
U.S. health care industry.
1
 It is estimated that prescription 
drug spending will continue to grow, and the price of the 
drugs is likely to increase over time.
2, 3
 Such high cost of 
prescription drugs often creates a barrier to medication 
access for patients.  Both insured and uninsured patients 
have reported cutting back on doses of their medicine
4
 or  
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even forgoing filling needed prescriptions.
1,4,5
 The 
consequences of medication non-use and underuse can lead 
to increased emergency room visits and other unnecessary 
health care resource use, which have been estimated to cost 
the U.S. healthcare system up to $100 billion per year.
6,7 
 
 
One alternative to alleviate patients’ financial burden to 
acquire needed medications is to seek help from patient 
assistance programs (PAPs) established by the 
pharmaceutical industry.  The pharmaceutical companies 
voluntarily participate in PAPs to offer a portion of their 
pharmaceutical products free or for a nominal fee to patients 
who meet the pre-determined PAP eligibility requirements. 
Each PAP created its benefit structure and qualifications that 
patients should comply with in order to receive their 
requested medications. Typically, patients can apply for PAPs 
either directly with the pharmaceutical companies or through 
informational websites. 
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A recent systematic review of the use of PAPs found that 
PAPs along with additional medication services (e.g., 
counseling) were associated with improved disease indicators 
for patients, positive economic outcomes for patients and 
institutions due to no-cost drug access, and avoidance of  
losses from uncompensated drug costs.
8 
However, causal 
inferences about the clinical or cost-effectiveness of PAPs 
could not be established due to limitations of the included 
studies’ designs.
8  
One study described the PAP application 
process as complex and labor intensive for health care 
providers who served in safety net clinics,
9
 though the study 
concluded that PAPs could still be helpful to fill the gaps in 
health insurance coverage if PAP eligibility criteria were more 
consistent.
9
Additional studies further demonstrated that 
PAPs could lead to cost savings for both health 
institutions
10,11
and low-income patients.
12,13 
All these 
previous studies suggested that PAP was one of the few 
options that the uninsured and underinsured could use to 
access necessary prescription drugs. The objective of this 
study was to determine if there was a difference between 
PAP eligibility criteria for commonly prescribed brand name 
and generic drugs in the U.S. Understanding this relationship 
may help health care providers and patients utilize these 
programs more effectively.  
 
Materials and Methods 
Data Sources and Study Sample 
We used publicly available data to identify the most 
commonly dispensed medications in the U.S. and PAP 
eligibility criteria based on the availability of these 
prescription drugs. All data collection was conducted from 
September to December 2009.   
  
First, to determine the America’s most commonly dispensed 
prescription drugs, a study sample was drawn from the list of 
Top 200 dispensed prescription drugs in 2008 from Pharmacy 
Times,
14
 which was published in May 2009.
 
This list provided 
each medication’s name, drug manufacturer, number of 
prescriptions dispensed, and its rank in the U.S. market. We 
excluded medications that had the same chemical 
formulation but were manufactured by different 
pharmaceutical companies from the study, because 
manufacturers’ rank in the U.S. market was not considered in 
this evaluation. Therefore, these medications were counted 
as one to avoid data duplication. We subsequently classified 
each prescription drug as brand name or generic and 
determined its clinical indications by searching the Internet 
Drug Index - RxList,
15
 which provided detailed and current 
pharmaceutical information on prescription drugs such as 
drug description, chemical and clinical data, indications, and 
side effects.  
 
Next, pharmaceutical industry–sponsored PAPs that offered 
medications in the Top 200 list were identified by searching 
RxAssist,
16
 a PAP database developed by Volunteers in Health 
Care (VIH).
  
RxAssist provides company contact information, 
eligibility requirements, and program applications on its 
website, and both patients and health care professionals can 
access this database to search for medications or 
pharmaceutical companies. For each prescription drug in the 
Pharmacy Times’ Top 200 list, we searched for PAPs that 
offered brand name and generic drugs and collected the 
relevant program eligibility criteria: (1) U.S. citizenship; (2) 
permanent residency; (3) restriction on prescription drug 
coverage; and (4) income limits. Our data search for PAPs did 
not include retailer discount programs created by national or 
regional retail pharmacies because those programs were not 
classified as PAPs. In addition, search results of the retail 
programs from RxAssist were not comprehensive. We chose 
RxAssist as our primary source to collect PAP eligibility criteria 
based on its capacity to yield more extensive results when 
searching for all PAPs that supplied either brand name or 
generic form of a specific medication, or both forms if 
applicable. We performed a quality check by using other 
websites (i.e. rxhope.com, pparx.org, and needymed.com) 
that provided similar PAP databases; however, the results 
from these websites either did not provide a full range of 
PAPs with respect to a specific medication, or multiple 
searches were required to obtain the same results as 
RxAssist’s. If further clarifications were needed, the 
pharmaceutical companies were contacted directly by phone, 
or their official PAP websites were searched to verify the 
eligibility information. 
 
 
Data Analysis  
Chi-square analysis was used to examine the difference 
between PAP eligibility criteria in relation to the types of 
medications (brand name or generic) offered by the 
programs. We then compared and determined whether the 
availability of brand name or generic drugs was significantly 
associated with PAP eligibility criteria. All statistical analyses 
were conducted using STATA software, version SE 11.0 
(StataCorp, College Station, Texas, USA).  The tests were two-
tailed, and p-value < 0.05 was deemed to be statistically 
significant.  
 
Results 
A total of 200 chemical entities were included from the list of 
Top 200 dispensed prescription drugs. We excluded 64 
prescription drugs that contained duplicate chemical 
formulation. The final sample consisted of 136 unique 
chemical entities with prescription status in the U.S. Of these, 
111 (82%) were offered through PAPs.  Sixty-nine (62%) of 
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these medications were brand name, 29 (26%) were generic, 
and 13 (12%) were available in both forms. 
 
We found that most of these medications were for the 
treatments of chronic conditions such as heart-related 
diseases, asthma, depression, and epilepsy (Table 1).  Overall, 
medications for hypertension were most likely to be offered 
by PAPs and were available in both brand name and generic 
forms. PAPs sponsored by pharmaceutical companies only 
supplied brand name drugs to qualifying patients. Pfizer, 
GlaxoSmithKline, and Johnson & Johnson provided more 
pharmaceutical products compared with other drug 
companies (Table 2). We also found two pharmacy 
businesses, which were not the originator manufacturers, 
established their version of PAPs to offer low-cost or free 
medications to eligible patients (Table 2). One of these 
pharmacy businesses was operated by Xubex 
Pharmaceuticals, an online mail-order pharmacy that offered 
the majority of generic medications and some brand name 
drugs in the Top 200 list. Patients were typically responsible 
for some fees in different Xubex’s PAPs. For example, 
patients could pay $20 for a 90-day supply if he or she was 
qualified for Xubex Pharmaceutical Services program. The 
other pharmacy business was Rx Outreach, a subsidiary of a 
pharmacy benefit management company (i.e. Express 
Scripts), and it offered generic drugs to low-income patients 
and required patients to pay a discounted price for 
medications based on its program’s tiered formulary.  
 
We observed differences in numbers of available brand name 
and generic drugs in relation to PAP eligibility requirements. 
As shown in Table 3, slightly more than two-thirds (68.3%) of 
brand name drugs were offered by PAPs that required U.S. 
citizenship/permanent residency; however, this criterion was 
not needed for generic drugs. PAPs also had different 
requirements for patients who had prescription coverage—
mainly for privately insured and Medicare Part D 
beneficiaries. Based on our findings, nearly 82.9% of brand 
name drugs were offered by PAPs that required applicants to 
have no prescription coverage, whereas, this requirement did 
not apply to generic drugs.  Patients who had prescription 
plans might be eligible for Xubex Pharmaceuticals’ Co-pay 
program, which would cover all or a part of patients’ co-
payment; however, Medicare Part D patients were not 
qualified for this program. Instead, Part D patients could 
apply for Xubex Free-Medication program and Xubex 
Pharmaceutical Services program that only offered generic 
medications with some fees. Overall, the eligibility 
information for Medicare Part D beneficiaries varied greatly 
across PAPs, as many programs did not provide specific 
details of their policy on Part D coverage, or such information 
was not available. Some programs stated that Part D patients 
could still submit applications and their claims would be 
evaluated on a case-by-case basis, depending on their 
financial situation and insurance status. We also found that 
some pharmaceutical companies established special PAPs 
(Table 4) to serve only Part D patients for certain medications 
in the Top 200 list. Apart from meeting the aforementioned 
PAP eligibility requirements, these Part D applicants needed 
to submit other supplementary documents to complete the 
application process (Table 4).  In terms of PAP’s income limits 
requirement, patients needed to meet specific income 
standards set by the programs in order to be qualified for 
brand name drugs (91.5%) and all generic drugs. The typical 
range of PAP income-limit requirement was from $10,890 to 
$43,320 for an individual, and from $14,710 to $58,280 for a 
family size of two. Some programs would make exceptions if 
patients could prove financial or medical hardship.  
  
Our results from chi-square analysis suggested that there 
were statistically significant differences between brand name 
and generic drugs offered by PAPs based on eligibility criteria 
(Table 3). We found that brand name drugs were more 
available to patients who were U.S. citizens/permanent 
residents (p<0.001) and those who did not have prescription 
drug coverage (p<0.001) than generic drugs. When examining 
income limits requirements, we found that the availability of 
medications did not differ significantly between brand name 
and generic drugs (p=0.051). 
 
Discussion 
Our findings suggest that the availability of types of 
medication offered by PAPs is associated with program 
eligibility criteria. Overall, brand name and generic drugs are 
available to low-income patients. In order to be qualified to 
receive brand name medications, most patients must comply 
with PAP requirements for citizenship/permanent residency, 
restriction on prescription drug coverage, and income limits. 
Applicants who applied for generic drugs only needed to 
meet the income limits requirements. We found that patients 
who were low-income U.S. citizens/permanent residents 
without prescription drug coverage were more likely to 
receive brand name drugs through PAPs than those who did 
not meet all these criteria. However, the income bracket 
required by PAPs is very broad, and every program has a 
specific standard, ranging from 100% to 400% of federal 
poverty level.
17,18 
As a result, patients in different low-income 
strata will have unequal access to medications offered by 
PAPs. Moreover, we found that privately insured and 
Medicare Part D patients were usually not qualified to apply 
for PAPs that offered brand name drugs. Additionally, 
because of varying levels of eligibility requirements among 
the programs, the application process could become even 
more complex for Part D patients who may need more than 
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one drug for their disease management. Given the observed 
variations of eligibility requirements for Part D patients, we 
were unable to assess the difference in PAP eligibility criteria 
for Part D prescription coverage in terms of the availability of 
medications.
 
 
With the current high health costs and economic recession, 
PAPs can provide safety-net assistance to patients who have 
no choice but to bear high drug cost, especially for chronically 
ill Americans who have been reported to have medication 
non-adherence due to cost pressure.
19
 The Department of 
Health and Human Services has already recognized the 
significant role of PAPs in providing safety net assistance to 
indigent patients and the chronically ill.
20 
We found that 82% 
of the top 200 commonly dispensed prescription drugs in the 
U.S. in 2008 were available through PAPs, compared with 
only 53% of dispensed prescription drugs in 1999.
21
Although 
this finding indicates that there is an increasing availability of 
prescription drugs offered by PAPs, our study suggested that 
some patients had limited access to the programs due to PAP 
eligibility requirements, especially for those with prescription 
drug coverage. PAPs’ restriction on prescription drug 
coverage for brand name drugs may have unintended 
consequences for the insured who have inadequate drug 
coverage, in which co-payment, co-insurance, and 
deductibles can be very high and, subsequently, put some 
specialty medications out of reach even for patients with 
purported prescription plan.  For Medicare Part D patients, 
the variations in eligibility requirements make the PAP 
application process cumbersome, as some patients may not 
have a steady income and are required to submit multiple 
applications to determine whether they are qualified for 
PAPs. The situation could become more difficult when Part D 
beneficiaries are in doughnut hole (i.e. coverage gap) where 
they are responsible for uncovered prescription expenses and 
this creates a greater financial burden for them to obtain 
needed medications without PAP’s help. If PAP eligibility 
requirements could be better structured, these programs 
could be more accessible to low-income insured patients to 
obtain medications when other resources in the health 
system are exhausted.  For example, details regarding the 
eligibility requirements for Medicare Part D beneficiaries and 
privately insured patients should be explicitly stated; clearer 
information disclosure will help patients access PAPs without 
confusion.  In addition, an electronic database with a 
standardized PAP application could help reduce excessive 
administration costs and time required to complete complex 
paperwork for both health institutions and patients.   
 
Besides the pharmaceutical industry-sponsored PAPs, 
discounted generic prescription drug program initiated by 
some major pharmacy chains and retailers (e.g. Walgreen, 
CVS, Wal-Mart) in recent years may serve as an alternative to 
help uninsured and underinsured patients acquire cost-saving 
generic medications
22.23
. For instance, these pharmacy chains 
typically offer 30- or 90-day supply of select generic drugs for 
$4 or $15, respectively; generic antibiotics are also provided 
to the customers with prescription plans at no additional 
costs
22,23
.  It is important to note that, while these retail 
pharmacy-supported programs can have some significant 
impacts on improving patients’ access to prescription drugs 
and medication adherence, more studies are needed to 
assess the quality and safety of these pharmaceutical 
products, according to a recent study
22
.  
 
The future of PAPs remains uncertain, as the Patient 
Protection and Affordable Care Act (PPACA) requires 
“qualified health plans” to include prescriptions in essential 
health benefits.
24,25
 If a drug plan becomes mandatory, then 
the use of PAPs will depend on the levels of new prescriptions 
coverage, which may differ.
26,27
 In 2011, Part D patients in the 
doughnut hole started receiving 50% discount on brand name 
drugs from manufacturers and 7% discount on generic 
medications plus a $250 check from the federal government 
in accordance with PPACA.
28
 However, these subsidies and 
one-time check do not completely eliminate the doughnut 
hole, and there is a concern about manufacturers raising the 
price of brand name drugs to mitigate their loss.
29
 Until more 
details are clarified, there might still be a financial challenge 
for some patients to pay for their prescription drugs, and 
health care providers will have to play a role in assisting 
patients to understand their options for cost-effective 
medications. To better understand the role of PAPs, future 
research should assess how PAPs can benefit patients 
following the health insurance market reform, and whether 
PAPs are cost-effective when universal prescription coverage 
is mandated according to PPACA.  More research should 
examine how PAPs could assist Medicare Part D patients after 
the new income-related premium policy was implemented in 
2011, which had an estimated annual growth rate of 7%,
30
 
and before the doughnut hole is fully eliminated in 2020.
30
  
 
Limitations 
Our assessment of the differences in PAP eligibility 
requirements and availability of types of prescription drugs 
has limitations. First, we evaluated PAP eligibility 
requirements for Medicare Part D beneficiaries, but there 
were numerous variations in criteria across several programs, 
and most information was not readily available. As a result, 
we cannot determine whether having Medicare Part D 
coverage was associated with the types of prescription drugs 
offered by PAPs. Second, we only used RxAssist database to 
identify PAPs that offered the most commonly dispensed 
medications in the U.S. Thus, our results have limited ability 
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to predict the relationship between PAP eligibility 
requirements and availability of prescription drugs if data 
from other informational websites (e.g. rxhope.com, 
pparx.org, and needymed.com) are used. However, the 
quality check we performed on other websites showed that 
RxAssist provided the most comprehensive data to achieve 
the objectives of this study. 
 
 
Conclusion 
Our study demonstrated that the availability of brand name 
and generic drugs provided by PAP is associated with PAP 
eligibility criteria. Patients without citizenship/permanent 
residency, with prescription drug coverage, or at certain 
lower-income levels are likely to have limited access to these 
programs. PAP procedure should be standardized and 
simplified to improve medication access for those who need 
assistance. Future studies are needed to understand the 
extended role of PAPs in the current environment of health 
care reform. 
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Table 1: Indications for the Most Commonly Dispensed Prescription Drugs in 2008 Provided by Patient Assistance Programs 
 
Indication Number of Drugs Available Brand Availability Generic Availability 
Allergy 4 3 1 
Anemia 1 0 1 
Anxiety/Panic Disorder 4 0 4 
Asthma 6 5 1 
Attention Deficit Hyperactivity Disorder (ADHD) 1 1 0 
Bacterial Infection 6 5 1 
Benign Prostatic Hyperplasia 1 1 0 
Cholesterol 7 6 1 
Chronic Obstructive Pulmonary Disease (COPD) 1 1 0 
Dementia 2 2 0 
Depression 7 6 1 
Diabetes 4 3 1 
Edema 1 0 1 
Epilepsy 7 4 3 
Erectile Dysfunction 2 2 0 
Fungal Infection 2 1 1 
Gastrointestinal Disorder/Symptom 6 5 1 
Genital Herpes /Herpes Zoster 1 1 0 
Heart Diseases 8 4 4 
Hypertension/ Blood Pressure 19 9 10 
Hyperurcemia 1 0 1 
Hypokalemia 2 0 2 
Inflammation (autoimmune disease) 1 0 1 
Insomnia 3 2 1 
Menopause 1 1 0 
Migraine 1 1 0 
Muscle Spasm/ condition 4 2 2 
Osteoporosis 3 3 0 
Pain Management 6 5 1 
Rheumatoid Arthritis 3 1 2 
Schizophrenia 4 4 0 
Smoking Cessation 1 1 0 
Stroke/Embolism 1 1 0 
Thyroid Hormone Treatment 2 1 1 
Urinary Incontinence 1 1 0 
Total 124 82 42 
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Table 2: Types of Top 200 Dispensed Prescription Drugs in 2008 Provided by 
             Pharmaceutical Industry-Sponsored Patient Assistance Programs 
 
Pharmaceutical Manufactures 
 Number of 
Drugs 
Brand-Name Drugs 
Available 
Generic Drugs 
Available 
Prescriber Signature 
Abbott 4 4 0 Physician 
AstraZeneca 
Pharmaceuticals 
4 4 0 
Physician 
Boehringer Ingelheim 
Cares Foundation 
3 3 0 
Physician 
Bristol-Myers Squibb 4 4 0 Physician 
Daiichi Sankyo 2 2 0 Physician 
Eisai 1 1 0 Physician 
Eli Lilly 4 4 0 Physician 
Endo Pharmaceutical 1 1 0 Physician 
Forest Pharmaceutical 4 4 0 Physician 
GlaxoSmithKline 11 11 0 Any Health Care 
Prescriber 
Johnson & Johnson 7 7 0 Physician 
King Pharmaceutical 1 1 0 Physician 
Mallinckrodt 1 1 0 Not Required 
Merck 4 4 0 Physician/Physician 
Assistant 
Merck/Schering-Plough 2 2 0 Physician 
Novartis Pharmaceuticals 1 1 0 Physician 
OcuSoft Inc. 1 1 0 Physician 
Pfizer 12 12 0 Physician 
Procter & Gamble 
Pharmaceuticals 
1 1 0 Physician 
Purdue Pharma 1 1 0 Physician 
Roche Pharmaceutical 1 1 0 Physician 
Sanofi-Aventis 2 2 0 Physician 
Schering Corporation 4 4 0 Physician 
Takeda Pharmaceuticals 
America 
2 2 0 Physician 
Teva Pharmaceutical 1 1 0 Physician 
Wyeth Pharmaceutical 3 3 0 Physician 
Pharmacy Business 
 Number of 
Drugs 
Brand-Name Drugs 
Available 
Generic Drugs 
Available 
Prescriber 
Signature 
XUBEX Pharmaceutical 51 13 38 Not Required 
Rx Outreach 
34 0 34 
N/A 
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Table 3: Availability of Brand-Name versus Generic Prescription Drugs 
        by Patient Assistance Programs Eligibility Requirements 
 
Availability of Top 200 Dispensed Prescriptions in 2008 
Eligibility Criteria Required by Patient 
Assistance Programs (PAP) Brand Name Generic Pearson’s (χ
2
); p 
US Citizenship 68.3% 0% 52.3; < 0.001 
US Permanent Residency 68.3% 0% 52.3; < 0.001 
Prescription Coverage not Allowed 82.9% 0% 77.12; < 0.001 
Income Limits 91.5% 100% 3.80;  = 0.051 
 
 
 
Table 4: Selected Patient Assistance Programs for Medicare Part D Patients 
 
Pharmaceutical Companies Patient Assistance Programs Additional Requirements Prescriber Signature 
Astrazeneca 
Pharmaceuticals 
AZ prescription savings 
program for people with 
Medicare Part D 
 Financial information 
 Prescription 
 Year-to-date prescription spend 
history 
Physicians 
 
Boehringer Ingelheim 
 
Boehringer Ingelheim Cares 
Foundation, Inc. (PAP for 
Medicare Beneficiaries)  
 
 Financial low-income subsidy 
denial for those with income less 
135% of FPL 
 
Physicians 
 
Eli Lilly 
 
Lilly Medicare Answers 
Program 
 
 Financial low-income subsidy 
denial 
 
Not required 
 
GlaxoSmithKline 
 
GSK Access 
 
 Financial information 
 Prescription 
 Copy of patients’ Medicare Part D 
card 
 Low Income Subsidy Notice of 
Denial (if applicable) 
 Documentation for all sources of 
income from each member of the 
applicant’s household may be 
required  
 
Not required 
 
 
 
 
 
 
 
